FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291675165> ?p ?o ?g. }

• W4291675165 endingPage "e1335" @default.
• W4291675165 startingPage "e1326" @default.
• W4291675165 abstract "Typhoid fever is a substantial public health problem in Africa, yet there are few clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of Typbar TCV in Malawi.This substudy was nested within a phase 3, double-blind, parallel design, randomised controlled trial of TCV in children from Ndirande Health Centre in Ndirande township, Blantyre, Malawi. To be eligible, participants had to be aged between 9 months and 12 years with no known immunosuppression or chronic health conditions, including HIV or severe malnutrition; eligible participants were enrolled into three strata of approximately 200 children (9-11 months, 1-5 years, and 6-12 years), randomly assigned (1:1) to receive TCV or control (meningococcal serogroup A conjugate vaccine [MCV-A]) intramuscularly. Serum was collected before vaccination and at 28 days and 730-1035 days after vaccination to measure anti-Vi antibodies by ELISA. Because of COVID-19, day 730 visits were extended up to 1035 days. This nested substudy evaluated reactogenicity, safety, and immunogenicity by age stratum. Safety outcomes, analysed in the intention-to-treat population, included solicited adverse events within 7 days of vaccination (assessed on 3 separate days) and unsolicited adverse events within 28 days of vaccination. This trial is registered with ClinicalTrials.gov, NCT03299426.Between Feb 22 and Sept 6, 2018, 664 participants were screened, and 631 participants were enrolled and randomly assigned (320 to the TCV group and 311 to the MCV-A group). 305 participants in the TCV group and 297 participants in the MCV-A group were vaccinated. Among TCV recipients, anti-Vi IgG geometric mean titres increased more than 500 times from 4·2 ELISA units (EU)/mL (95% CI 4·0-4·4) at baseline to 2383·7 EU/mL (2087·2-2722·3) at day 28, then decreased to 48·0 EU/mL (39·9-57·8) at day 730-1035, remaining more than 11 times higher than baseline. Among MCV-A recipients, anti-Vi IgG titres remained unchanged: 4·3 EU/mL (4·0-4·5) at baseline, 4·4 EU/mL (4·0-4·7) on day 28, and 4·6 EU/mL (4·2-5·0) on day 730-1035. TCV and MCV-A recipients had similar solicited local (eight [3%] of 304, 95% CI 1·3-5·1 and three [1%] of 293, 0·4-3·0) and systemic (27 [9%] of 304, 6·2-12·6 and 27 [9%] of 293, 6·4-13·1) reactogenicity. Related unsolicited adverse events occurred similarly in TCV and MCV-A recipients in eight (3%) of 304 (1·3-5·1) and eight (3%) of 293 (1·4-5·3).This study provides evidence of TCV safety, tolerability, and immunogenicity up to 730-1035 days in Malawian children aged 9 months to 12 years.Bill & Melinda Gates Foundation." @default.
• W4291675165 created "2022-08-15" @default.
• W4291675165 creator A5011013683 @default.
• W4291675165 creator A5013435324 @default.
• W4291675165 creator A5014103708 @default.
• W4291675165 creator A5015444709 @default.
• W4291675165 creator A5017702228 @default.
• W4291675165 creator A5018146103 @default.
• W4291675165 creator A5021333933 @default.
• W4291675165 creator A5026332423 @default.
• W4291675165 creator A5033785570 @default.
• W4291675165 creator A5034013271 @default.
• W4291675165 creator A5037307507 @default.
• W4291675165 creator A5039765477 @default.
• W4291675165 creator A5039890048 @default.
• W4291675165 creator A5041683451 @default.
• W4291675165 creator A5051550648 @default.
• W4291675165 creator A5055641523 @default.
• W4291675165 creator A5057610886 @default.
• W4291675165 creator A5060283208 @default.
• W4291675165 creator A5081409930 @default.
• W4291675165 creator A5088278871 @default.
• W4291675165 creator A5089239945 @default.
• W4291675165 date "2022-09-01" @default.
• W4291675165 modified "2023-10-11" @default.
• W4291675165 title "Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial" @default.
• W4291675165 cites W1964049648 @default.
• W4291675165 cites W2007913880 @default.
• W4291675165 cites W2046418337 @default.
• W4291675165 cites W2049532298 @default.
• W4291675165 cites W2114673506 @default.
• W4291675165 cites W2123999602 @default.
• W4291675165 cites W2141031524 @default.
• W4291675165 cites W2142665814 @default.
• W4291675165 cites W2159903731 @default.
• W4291675165 cites W2324367298 @default.
• W4291675165 cites W2593299699 @default.
• W4291675165 cites W2603477349 @default.
• W4291675165 cites W2743014102 @default.
• W4291675165 cites W2788800189 @default.
• W4291675165 cites W2802302134 @default.
• W4291675165 cites W2883397066 @default.
• W4291675165 cites W2921283965 @default.
• W4291675165 cites W2970920968 @default.
• W4291675165 cites W2982602544 @default.
• W4291675165 cites W2993293153 @default.
• W4291675165 cites W3027293974 @default.
• W4291675165 cites W3044675763 @default.
• W4291675165 cites W3165576950 @default.
• W4291675165 cites W3190947740 @default.
• W4291675165 cites W3200770050 @default.
• W4291675165 cites W4210463927 @default.
• W4291675165 cites W4226553046 @default.
• W4291675165 cites W4238107105 @default.
• W4291675165 doi "https://doi.org/10.1016/s2214-109x(22)00275-3" @default.
• W4291675165 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35961356" @default.
• W4291675165 hasPublicationYear "2022" @default.
• W4291675165 type Work @default.
• W4291675165 citedByCount "12" @default.
• W4291675165 countsByYear W42916751652022 @default.
• W4291675165 countsByYear W42916751652023 @default.
• W4291675165 crossrefType "journal-article" @default.
• W4291675165 hasAuthorship W4291675165A5011013683 @default.
• W4291675165 hasAuthorship W4291675165A5013435324 @default.
• W4291675165 hasAuthorship W4291675165A5014103708 @default.
• W4291675165 hasAuthorship W4291675165A5015444709 @default.
• W4291675165 hasAuthorship W4291675165A5017702228 @default.
• W4291675165 hasAuthorship W4291675165A5018146103 @default.
• W4291675165 hasAuthorship W4291675165A5021333933 @default.
• W4291675165 hasAuthorship W4291675165A5026332423 @default.
• W4291675165 hasAuthorship W4291675165A5033785570 @default.
• W4291675165 hasAuthorship W4291675165A5034013271 @default.
• W4291675165 hasAuthorship W4291675165A5037307507 @default.
• W4291675165 hasAuthorship W4291675165A5039765477 @default.
• W4291675165 hasAuthorship W4291675165A5039890048 @default.
• W4291675165 hasAuthorship W4291675165A5041683451 @default.
• W4291675165 hasAuthorship W4291675165A5051550648 @default.
• W4291675165 hasAuthorship W4291675165A5055641523 @default.
• W4291675165 hasAuthorship W4291675165A5057610886 @default.
• W4291675165 hasAuthorship W4291675165A5060283208 @default.
• W4291675165 hasAuthorship W4291675165A5081409930 @default.
• W4291675165 hasAuthorship W4291675165A5088278871 @default.
• W4291675165 hasAuthorship W4291675165A5089239945 @default.
• W4291675165 hasBestOaLocation W42916751651 @default.
• W4291675165 hasConcept C126322002 @default.
• W4291675165 hasConcept C159047783 @default.
• W4291675165 hasConcept C159654299 @default.
• W4291675165 hasConcept C168563851 @default.
• W4291675165 hasConcept C187212893 @default.
• W4291675165 hasConcept C197934379 @default.
• W4291675165 hasConcept C203014093 @default.
• W4291675165 hasConcept C22070199 @default.
• W4291675165 hasConcept C2777704310 @default.
• W4291675165 hasConcept C2779583294 @default.
• W4291675165 hasConcept C2780868878 @default.
• W4291675165 hasConcept C2908647359 @default.
• W4291675165 hasConcept C520601542 @default.
• W4291675165 hasConcept C71924100 @default.

• next